Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

The report, from 340B Health, claims that changes proposed by major drugmakers to replace upfront discounts with post-sale rebates for outpatient drugs would hit safety-net hospitals with significant ...

The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Covenant Health is now offering CAR T-cell therapy at the Joe Arrington Cancer Research & Treatment Center, marking a major advancement in personalized cancer treatment in West Texas.

Key Points Prime Medicine posted GAAP revenue of $1.1 million, missing analyst expectations by over 70% (GAAP). Reported net loss (GAAP) narrowed to $52.6 million, driven by reduced research and ...

By Lewis Krauskopf NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump ...

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

Bristol-Myers Squibb recently saw a 6.39% drop in its stock value, with weak momentum and bearish signals from technical ...